Angel News

Back to Homepage

5th October 2020

24 Haymarket backs £40.6m funding for Immune Regulation Limited

Immune Regulation Limited, a US and UK based clinical stage biotechnology company, has closed a Series B funding round led by Boston based Morningside Ventures, alongside existing shareholders including London based 24Haymarket.


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage